Pitavastatin: focus on safety and drug interactions
Pitavastatin is a drug from the group of HMG-CoA reductase inhibitors, which has good lipid-lowering efficacy and has no significant effect on the risk of diabetes mellitus. This drug is non significantly metabolized by the P450 cytochrome system, which minimizes the risk of possible drug-drug inter...
Saved in:
Main Authors: | Larisa O. Minushkina, Dmitry A. Zateyshchikov |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Concilium Medicum
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/64f2f979611d4d8f8eeeb8ca730ad066 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Statins and diabetes: focus on pitavastatin
by: Soreiia A. Urazgildeeva
Published: (2020) -
Obituary: Academician of the Russian Academy of Sciences, Professor Rafael G. Oganov 09.12.1937–24.09.2020. Professor Anatoliy N. Britov 15.01.1934–03.12.2020
by: Editorial bord Cardiosomatics
Published: (2021) -
American physician Samuel A. Levine and his contribution into the cardiac rehabilitation
by: David M. Aronov
Published: (2021) -
Human serum metabolomic analysis reveals progression for high blood pressure in type 2 diabetes mellitus
by: Li Li, et al.
Published: (2021) -
Quality gaps in screening and monitoring for postoperative hyperglycemia in a Canadian hospital: a retrospective cohort study
by: Anna Cameron, et al.
Published: (2021)